Shire (NASDAQ:SHPG)‘s stock had its “buy” rating reissued by analysts at B. Riley in a research report issued to clients and investors on Tuesday.

Several other equities analysts have also issued reports on SHPG. BidaskClub lowered shares of Shire from a “hold” rating to a “sell” rating in a report on Thursday, August 16th. ValuEngine raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, August 24th. Sanford C. Bernstein downgraded shares of Shire from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 4th. Evercore ISI downgraded shares of Shire from an “outperform” rating to a “market perform” rating and set a $196.00 price objective for the company. in a research report on Tuesday, September 4th. Finally, Berenberg Bank downgraded shares of Shire from a “buy” rating to a “hold” rating in a research report on Friday, September 7th. Nine research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $201.11.

Shares of NASDAQ:SHPG opened at $171.50 on Tuesday. The company has a market capitalization of $53.37 billion, a P/E ratio of 11.32, a PEG ratio of 1.59 and a beta of 1.01. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 0.36. Shire has a 1 year low of $123.73 and a 1 year high of $182.47.

Shire (NASDAQ:SHPG) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 earnings per share for the quarter, missing analysts’ consensus estimates of $3.65 by ($0.01). The company had revenue of $3.87 billion for the quarter. Shire had a return on equity of 12.70% and a net margin of 30.63%. The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.81 earnings per share. As a group, equities analysts predict that Shire will post 15.08 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in SHPG. Centaurus Financial Inc. bought a new stake in Shire during the second quarter valued at approximately $102,000. Rehmann Capital Advisory Group lifted its holdings in Shire by 226.9% during the second quarter. Rehmann Capital Advisory Group now owns 680 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 472 shares in the last quarter. Valeo Financial Advisors LLC purchased a new position in shares of Shire in the second quarter worth $129,000. Vectors Research Management LLC purchased a new position in shares of Shire in the third quarter worth $133,000. Finally, Cornerstone Wealth Management LLC purchased a new position in shares of Shire in the second quarter worth $145,000. Hedge funds and other institutional investors own 20.49% of the company’s stock.

Shire Company Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Read More: Analyzing a company’s cash flow statement

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.